Bioequivalence (BE), Safety and Efficacy Consideration for Injectable Complex Formulations

Duxin Sun, Ph.D. and Amit Pai, Pharm.D.

J.G. Searle Endowed Professor
Director of Pharmacokinetics Core
Department of Pharmaceutical Sciences
University of Michigan
Ann Arbor, MI 48109
Challenges for Bioequivalence (BE) Standards of Injectable Complex Formulations

- Plasma AUC and Cmax may not be able to distinguish difference between generic and RLD injectable complex formulations.

- Total drug plasma profiles cannot distinguish drug-carrier delivered together or separately for injectable complex formulations.

- Injectable complex formulations may have different intracellular uptake in cancer cells, which may not correlate with plasma profiles.

- Injectable complex formulations have formulation specific tissue distribution, which may not correlate with plasma profiles, but correlate with efficacy and toxicity profiles.
Albumin Paclitaxel Nanoparticle (Abraxane) Shows Different Clinical Efficacy From Paclitaxel --- not BE

- **Paclitaxel indications**
  - Breast cancer, Ovarian cancer, non-small cell lung cancer, AIDS related sarcoma

- **Abraxane indications**
  - Metastatic breast cancer
    - After failure of combination chemotherapy for metastatic disease or relapse with 6 months of adjuvant chemotherapy
  - Locally advanced or metastatic non-small cell lung cancer
    - First line treatment in combination with carboplatin
  - Metastatic pancreatic cancer
    - First line therapy in combination of gemcitabine
Plasma AUC and Cmax May not be Able to Distinguish Difference Between Generic and RLD Injectable Complex Formulations

AUC has no Difference between Abraxane and Taxol in Humans --- BE?
Total Drug Plasma Profiles Can not Distinguish Drug-carrier Delivered Together or Separately for Injectable Complex Formulations in Humans

Humans: cannot distinguish

Mice: can distinguish
Injectable Complex Formulations May Have Different Intracellular Uptake in Cancer cells, which May not Correlate With Plasma Profiles

Abraxane has higher intracellular uptake than poor HSA formulation
Injectable Complex Formulations Have Formulation Specific Tissue Distribution, Which May not Correlate with Plasma Profiles, but Correlate with Efficacy

Abraxane and mouse Abraxane have high accumulation in lung, pancreas, and breast fatpad, which correlates with clinical indication.
Proposed Studies for Injectable Complex Formulations

1. Formulate Different Quality of Albumin-Bound Paclitaxel

**Pharmaceutical Equivalence**

- particle size and morphology
- surface potential
- paclitaxel crystallinity
- fraction of free and bound paclitaxel or albumin in reconstituted suspension
- nature of bond between paclitaxel and albumin
- *in vitro* release kinetics
- albumin characterization

![Formulation Development Diagram](image.png)

- F$_{1,2}$-AB-PAC
- PAC
- AB-PAC
- Mouse AB-PAC
- Syringe
Proposed Studies for Injectable Complex Formulations

2. Study Tissue Distribution, Imaging, and Cellular Uptake of Different Quality of Albumin-Bound Paclitaxel
Proposed Studies for Injectable Complex Formulations

3. PBPK Modeling of Drug Distribution and New BE Standard

New BE Standards Based on PBPK and Biodistribution